Strategic Overview
FY21 unfolded during a period of global disruption. Despite operational challenges, the focus remained firm on innovation, portfolio expansion, and strengthening research infrastructure. The year demonstrated agility in execution and a commitment to advancing critical care.
Product Launch Milestones
Three major products were successfully launched:
- Velimixin – A proprietary Supra Molecular Cationic (SMC) complex of Polymyxin B designed to reduce drug-induced kidney injury associated with conventional polymyxins.
- Ronem Forte (Meropenem 2g) – First DCGI-approved high-dose formulation in India for critically ill patients requiring intensive antimicrobial therapy.
- Cloti-Xa (Enoxaparin Sodium) – Introduced with NovaGuard® SA Pro safety system to minimise needle-stick injury risks in hospital environments.
Technology Absorption
To enhance research depth, four advanced platforms were installed:
- Hollow Fibre
- Rapid Equilibrium Dialysis (RED) Device
- LC-MS/MS analytical system
- Atomic Absorption Spectrometry (AAS)
These technologies strengthened antibiotic development modelling and analytical precision.
Regulatory & Filing Progress
- 136 dossiers filed globally
- 133 market authorisations received
Strategic Collaborations
- Partnerships with SEDA (UK), NORTIS (US), SINTEF (Norway), and Newcells Biotech (UK)
FY21 reflected resilience in adversity, reinforcing scientific capability while expanding the critical care portfolio.